In 2012, AstraZeneca entered into a strategic relationship with Charles River Laboratories whereby preclinical safety packages comprising safety pharmacology, toxicology, formulation analysis, in vivo ADME, bioanalysis and pharmacokinetics studies are outsourced. New processes were put in place to ensure seamless workflows with the aim of accelerating the delivery of new medicines to patients. Here, we describe in more detail the AstraZeneca preclinical safety outsourcing model and the way in which a collaborative tool has helped to translate the processes in AstraZeneca and Charles River Laboratories into simpler integrated workflows that are efficient and visible across the two companies.

2012年，阿斯利康与查尔斯河实验室建立了战略合作关系，将包括安全药理学，毒理学，制剂分析，体内ADME，生物分析和药代动力学研究在内的临床前安全软件包外包。采取了新的流程以确保无缝的工作流程，以加快向患者提供新药的目的。在这里，我们将更详细地描述阿斯利康的临床前安全外包模型，以及协作工具如何帮助将阿斯利康和查尔斯河实验室的流程转化为更简单的集成工作流程，这些工作流程在两家公司中均有效且可见。